Can Wellbutrin (bupropion) be co‑prescribed with Paxil (paroxetine) in an adult patient without a history of seizures, eating disorders, or other contraindications and who is not taking strong CYP2D6‑inhibiting drugs?

Can Wellbutrin Be Given with Paxil?

Yes, Wellbutrin (bupropion) can be co-prescribed with Paxil (paroxetine), but this combination requires careful dose management due to a significant pharmacokinetic drug interaction. Bupropion is a potent CYP2D6 inhibitor that substantially increases paroxetine exposure, necessitating paroxetine dose reduction when initiating this combination 1, 2, 3.

Key Drug Interaction Mechanism

Bupropion potently inhibits CYP2D6, the primary enzyme metabolizing paroxetine. The FDA label for Wellbutrin explicitly states that bupropion inhibits CYP2D6 and can increase concentrations of antidepressants including paroxetine, recommending dose reduction of the CYP2D6 substrate when used concomitantly 1.

Magnitude of CYP2D6 Inhibition

• Bupropion demonstrates dose-dependent CYP2D6 inhibition, with 50% of patients on 300 mg/day or higher being phenoconverted from extensive metabolizers to poor metabolizer status 4
• At 150 mg/day bupropion, 19% of patients are phenoconverted to poor metabolizers, while this increases to 50% at doses ≥300 mg/day 4
• In vitro studies show paroxetine has an IC50 of 1.6 μM for inhibiting bupropion hydroxylation, indicating bidirectional interaction potential 2
• Clinical studies demonstrate bupropion can convert extensive CYP2D6 metabolizers to poor metabolizer phenotype, with metabolic ratios increasing from 0.012 to 0.418 3, 5

Clinical Evidence Supporting Combination Use

Despite the pharmacokinetic interaction, clinical studies demonstrate this combination can be used safely and effectively with appropriate monitoring. A prospective study of 18 patients combining bupropion SR 150 mg/day with SSRIs (including paroxetine) showed clinically significant benefit in 78% of partial responders or nonresponders, with 33% achieving full response 6.

Practical Benefits

• The combination improved sexual dysfunction, particularly decreasing orgasmic delay in both men and women 6
• Plasma monitoring revealed no statistically significant changes in paroxetine levels during the trial, though this may reflect the lower bupropion dose used (150 mg/day) 6
• Bupropion may be preferentially considered for patients with depression who also need smoking cessation support 7

Dosing Recommendations

Start with lower doses and titrate cautiously when combining these agents:

• Initiate bupropion at 150 mg/day when adding to existing paroxetine therapy to minimize CYP2D6 inhibition 6, 4
• Consider reducing paroxetine dose by 25-50% when initiating bupropion, particularly if using bupropion ≥300 mg/day 1, 4
• Monitor for increased paroxetine-related adverse effects (sedation, anticholinergic effects, sexual dysfunction) that may indicate excessive paroxetine exposure 8
• If escalating bupropion beyond 150 mg/day, reassess paroxetine dosing and consider therapeutic drug monitoring 4

Safety Monitoring Requirements

Close monitoring is essential when using this combination:

• Monitor blood pressure and heart rate, especially during the first 12 weeks, as both agents can affect cardiovascular parameters 7, 9
• Assess for serotonin syndrome symptoms, though risk is lower with this combination compared to MAOI combinations 8
• Screen for mood changes, suicidal ideation, and neuropsychiatric adverse effects, particularly in patients under 24 years 7
• Evaluate for increased anticholinergic effects, as paroxetine has more anticholinergic activity than other SSRIs 8, 10

Contraindications and Precautions

Absolute contraindications to bupropion that preclude this combination:

• Seizure disorder or history of seizures (bupropion lowers seizure threshold) 1
• Current or prior diagnosis of bulimia or anorexia nervosa (higher seizure incidence) 1
• Concurrent MAOI use or within 14 days of MAOI discontinuation 1
• Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs 1

Use with caution in:

• Patients with cardiovascular disease (monitor heart rate and blood pressure closely) 9
• Patients with hypertension, particularly if uncontrolled 9, 7
• Patients requiring opioid therapy (naltrexone component in some bupropion formulations contraindicates this) 7

Alternative Considerations

If the drug interaction is problematic, consider these alternatives:

• SSRIs with less CYP2D6 dependence (citalopram, escitalopram, sertraline) have lower interaction potential with bupropion 8, 2
• Venlafaxine shows pharmacokinetic changes with bupropion (increased venlafaxine, decreased O-desmethylvenlafaxine) but may be better tolerated than paroxetine in some patients 6
• For patients requiring robust CYP2D6 substrate therapy, alternative antidepressants without significant CYP2D6 inhibition should be considered 11

Common Pitfalls to Avoid

• Do not assume standard paroxetine dosing is appropriate when adding bupropion—dose reduction is typically necessary 1, 4
• Do not overlook the dose-dependent nature of bupropion's CYP2D6 inhibition—higher bupropion doses require more aggressive paroxetine dose reduction 4
• Do not forget to reassess paroxetine dosing if bupropion is discontinued, as paroxetine requirements will increase 3, 5
• Do not combine with MAOIs or initiate within 14 days of MAOI discontinuation due to hypertensive crisis risk 1